



For immediate release April 10, 2013

Genovis to publish Q1 2013 report ahead of schedule

The Board of Directors of Genovis AB (publ) has decided to publish Q1 2013 report ahead of schedule.

The Interim Report for January-March, which was to be announced on April 24, will be published ahead of schedule. The new publication date for the report is April 16, 2013.

ABOUT GENOVIS

Genovis' business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: +46 (0)31-745 50 00

For additional information please contact:

Sarah Fredriksson, CEO of Genovis AB

Tel: +46 (0)46-10 12 35

e-mail: sarah.fredriksson@genovis.com